In the evolving field of neuro-scientific investigation, few compounds have garnered as much attention as P7C3-A20 peptide. As someone deeply invested in tracking advancements in cellular biochemistry and neuroprotective agents, I have spent considerable time analyzing the literature surrounding this fascinating aminopropyl carbazole. It is important to clarify that this information is intended strictly for research purposes; it does not constitute medical advice, and I do not advocate for human use of these compounds.
What is P7C3-A20?
At its core, P7C3-A20 is a highly active analogue of the original P7C3 molecule. It is widely recognized in laboratory settings as a potent neuroprotective agent. The chemical structure is designed to interact with nicotinamide phosphoribosyltransferase (NAMPT), an enzyme critical for the biosynthesis of NAD+. By acting as a NAMPT activator, the compound helps elevate cellular nicotinamide adenine dinucleotide (NAD+) levels, which are often deplet P7C3-A20 (CAS Number: 1235481-90-9) ed during periods of cellular stress or injury.
Key Research Findings and Mechanisms
The scientific community has documented several impressive properties of this compound in various models. When evaluating the data, it becomes clear why researchers are so focused on its potential:
* Blood-Brain Barrier Integrity: One of the most compelling findings is that P7C3-A20 has been shown to repair the blood-brain barrier. This is a critical factor in maintaining neurological homeostasis.
* Neuroprotection and Neuron Survival: The compound actively fosters the survival of neurons. By acting as an anti-apoptotic agent, it prevents programmed cell death in sensitive hippocampal regions.
* Mitigation of Neurodegeneration: Extensive studies indicate that P7C3-A20 treatment mitigates neurodegeneration in various models, including those investigating focal ischemia and chronic injury by ZB Loris · 2017 · Cited by 71 — P7C3-A20 treatment mitigates neurodegeneration and augments repair in the brain after focal ischemia, which translates into chronic behavioral improvement. .
* Behavioral Improvements: In preclinical models, P7C3-A20 treatment significantly improved behavioral outcomes, including memory and sensorimotor function, which translates into chro P7C3-A20 nic behavioral improvement.
* Anti-Inflammatory Properties: Beyond direct neuronal support, P7C3-A20 treatment suppressed neuroinflammation and protected retinal ganglion cells, demonstrating a multifaceted approach to cellular healt P7C3-A20, NAMPT activator; Proneurogenic agent (TBI3414) h.
Observ The manuscript reports that P7C3-A20 treatment significantly improved behavioral outcomes including sensorimotor and memory function compared to non-treated ations on Cognitive and Pathological Models
Perhaps the most exciting area of study involves its role in age-related cognitive decline. Recent data suggests that the molecule is able to reverse the brain pathology and cognitive decline in specific mouse models. Researchers have observed that it reduces microtubule-associated protein 1 light chain 3-II (LC3-II) levels, which is a marker often associated with autophagy-related processes in the brain.
Furthermore, because P7C3-A20 exerts an antidepressant-like effect and exerts P7C3-A20 is a small molecule which can act as a NAMPT activator; Proneurogenic agent. It is provided as a powder. antidepressant efficacy in mice, it is currently being scrutinized for its ability to enhance hippocampal neurogenesis. These findings are supported by evidence that it safely protects neurons in nonhuman primates, suggesting a robust profile that warrants further investigation.
Understanding the Research-Grade Context
When navigating the landscape of research chemicals, it is common to encounter the term "research-grade P7C3-A20 inhibitor" or "supplement." It is vital to distinguish between legitimate chemical suppliers and consumer-grade products. High-quality samples, typically verified by HPLC purity (often >99%), are the standard for epigenetic studies and cancer research.
The distinction between P7C3 and A20 is also important for researchers. While P7C3 is the parent compound, A20 is considered a more stable and effective derivative. For those interested in the technical specifications, the molecular weight is 506.21, and the CAS number is 1235481-90-9.
Conclusion
The body of research surrounding P7C3-A20 is vast and continues to grow. From helping to reduce neurological deficits in traumatic brain injury models to its potential in addres P7C3-A20 | CAS 1235481-90-9 - Selleck Chemicals sing complex neurodegenerative pathologies, the compound remains a cornerstone of current laboratory investigation. P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. As we look toward the future, the ability of this substance to promote endogenous reparative strategies remains one of the most promising avenues for understanding how we might one day support the delicate architecture of the brain.
*Disclaimer: This content is for informational and educatio Oct 23, 2020 — “This is the first time we've seen that P7C3-A20 can protect endothelial cells at the interface of the cardiovascular system and the brain, nal purposes only. It is not intended to provide medical advice, diagnosis, or treatment for any human condition.*